• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

囊性纤维化跨膜传导调节因子(CFTR)离子转运缺陷使上皮细胞易于在囊性纤维化中发生部分上皮-间质转化。

CFTR ion transport deficiency primes the epithelium for partial epithelial-mesenchymal transition in cystic fibrosis.

作者信息

Rodrigues Cláudia S, Canto Matilde, Torres Raquel, Railean Violeta, Ramalho Sofia S, Farinha Carlos M, Pankonien Ines, Amaral Margarida D

机构信息

BioISI-Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.

出版信息

Front Pharmacol. 2025 Aug 20;16:1655479. doi: 10.3389/fphar.2025.1655479. eCollection 2025.

DOI:10.3389/fphar.2025.1655479
PMID:40910003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12405223/
Abstract

INTRODUCTION

Cystic fibrosis (CF) is a monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a Cl/HCO ion channel located at the apical plasma membrane (PM) of epithelial cells. CFTR dysfunction disrupts epithelial barrier integrity, drives progressive airway remodelling and has been associated with epithelial-to-mesenchymal transition (EMT), a process in which cells lose epithelial properties and acquire mesenchymal characteristics. We previously demonstrated that mutant CFTR directly drives partial EMT, independently of secondary events such as bacterial infection or inflammation.

METHODS

Here, we investigated whether PM localisation of CFTR alone is sufficient to preserve epithelial integrity or if its ion transport function is also required using polarized CF bronchial epithelial (CFBE) cells expressing wt-, p.Phe508del-, or p.Gly551Asp-CFTR. While p.Phe508del-CFTR is retained in the endoplasmic reticulum (ER) and fails to traffic to the PM, p.Gly551Asp-CFTR reaches the PM but lacks ion transport function. To this end we assessed transepithelial electrical resistance (TEER), cell proliferation, wound healing, and expression of epithelial and mesenchymal markers by Western blot and immunofluorescence.

RESULTS

The degree of mesenchymal phenotype was higher in cells expressing p.Phe508del-CFTR vs. those expressing PM localized but non-functional p.Gly551Asp-CFTR. This was evidenced by lower TEER, higher expression of mesenchymal markers (N-cadherin, vimentin), and lower E-/N-cadherin ratio. Furthermore, both CF cells displayed delayed wound healing compared to wt-CFTR cells, while only p.Phe508del-CFTR cells, but not p.Gly551Asp-CFTR cells, showed increased cell proliferation. Moreover, treatment with CFTR modulators (CFTRm) partially restored tight junction integrity by increasing claudin-1 levels and E-/N-cadherin ratio in both mutant cells. TGF-β1 treatment induced EMT in all three cell lines by decreasing epithelial markers (E-cadherin, cytokeratin 18, claudin-1) while increasing N-cadherin levels. However, mesenchymal marker vimentin increased only in CF cells, and more prominently in p.Phe508del-CFTR than in p.Gly551Asp-CFTR cells. Additionally, CFTR inhibition in wt-CFTR cells, partially mimicked p.Gly551Asp-CFTR behaviour, i.e., reduced claudin-1 levels.

DISCUSSION

Altogether, these findings demonstrate that the loss of CFTR ion transport, despite the physical presence of (nonfunctional) CFTR at the PM, is enough to trigger partial EMT. However, the severity of the EMT phenotype worsens when CFTR is absent from the PM while also increasing susceptibility to TGF-β1-triggered EMT. Moreover, CFTRm only partially reverse this CF EMT state, indicating that full epithelial integrity will likely require targeting additional factors.

摘要

引言

囊性纤维化(CF)是一种单基因疾病,由囊性纤维化跨膜传导调节因子(CFTR)基因突变引起,该基因编码一种位于上皮细胞顶端质膜(PM)的Cl⁻/HCO₃⁻离子通道。CFTR功能障碍破坏上皮屏障完整性,导致进行性气道重塑,并与上皮-间质转化(EMT)相关,在这个过程中细胞失去上皮特性并获得间质特性。我们之前证明,突变型CFTR直接驱动部分EMT,独立于诸如细菌感染或炎症等继发事件。

方法

在此,我们使用表达野生型、p.Phe508del-或p.Gly551Asp-CFTR的极化CF支气管上皮(CFBE)细胞,研究单独的CFTR在质膜上的定位是否足以维持上皮完整性,或者其离子转运功能是否也有必要。虽然p.Phe508del-CFTR保留在内质网(ER)中,无法转运到质膜,但p.Gly551Asp-CFTR到达质膜但缺乏离子转运功能。为此,我们通过蛋白质免疫印迹和免疫荧光评估跨上皮电阻(TEER)、细胞增殖、伤口愈合以及上皮和间质标志物的表达。

结果

与表达定位在质膜但无功能的p.Gly551Asp-CFTR的细胞相比,表达p.Phe508del-CFTR的细胞中间质表型程度更高。这通过更低的TEER、更高的间质标志物(N-钙黏蛋白、波形蛋白)表达以及更低的E-钙黏蛋白/N-钙黏蛋白比值得以证明。此外,与野生型CFTR细胞相比,两种CF细胞的伤口愈合均延迟,而只有p.Phe508del-CFTR细胞,而非p.Gly551Asp-CFTR细胞,显示出细胞增殖增加。此外,用CFTR调节剂(CFTRm)处理通过增加两种突变细胞中的claudin-1水平和E-钙黏蛋白/N-钙黏蛋白比值,部分恢复紧密连接完整性。TGF-β1处理通过降低上皮标志物(E-钙黏蛋白、细胞角蛋白18、claudin-1)水平同时增加N-钙黏蛋白水平,在所有三种细胞系中诱导EMT。然而,间质标志物波形蛋白仅在CF细胞中增加,并且在p.Phe508del-CFTR细胞中比在p.Gly551Asp-CFTR细胞中更显著。此外,野生型CFTR细胞中的CFTR抑制部分模拟了p.Gly551Asp-CFTR的行为,即降低claudin-1水平。

讨论

总之,这些发现表明,尽管质膜上存在(无功能的)CFTR,但CFTR离子转运的丧失足以触发部分EMT。然而,当质膜上不存在CFTR时,EMT表型的严重程度会恶化,同时也增加了对TGF-β1触发的EMT的易感性。此外,CFTRm仅部分逆转这种CF EMT状态,表明完全的上皮完整性可能需要针对其他因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/90ee93a4bb7b/fphar-16-1655479-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/4b177e74b58c/fphar-16-1655479-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/30a9e21b4b01/fphar-16-1655479-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/8cd626911f03/fphar-16-1655479-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/00e14c296250/fphar-16-1655479-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/383844d9c483/fphar-16-1655479-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/90ee93a4bb7b/fphar-16-1655479-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/4b177e74b58c/fphar-16-1655479-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/30a9e21b4b01/fphar-16-1655479-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/8cd626911f03/fphar-16-1655479-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/00e14c296250/fphar-16-1655479-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/383844d9c483/fphar-16-1655479-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d7/12405223/90ee93a4bb7b/fphar-16-1655479-g006.jpg

相似文献

1
CFTR ion transport deficiency primes the epithelium for partial epithelial-mesenchymal transition in cystic fibrosis.囊性纤维化跨膜传导调节因子(CFTR)离子转运缺陷使上皮细胞易于在囊性纤维化中发生部分上皮-间质转化。
Front Pharmacol. 2025 Aug 20;16:1655479. doi: 10.3389/fphar.2025.1655479. eCollection 2025.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(有或没有增效剂)。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
4
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.用于囊性纤维化相关肺部疾病的局部囊性纤维化跨膜传导调节因子基因替代疗法。
Cochrane Database Syst Rev. 2016 Jun 17;2016(6):CD005599. doi: 10.1002/14651858.CD005599.pub5.
5
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.囊性纤维化患者非结核分枝杆菌肺部感染的抗生素治疗
Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039.
6
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.囊性纤维化的增效剂(针对III类和IV类突变的特定疗法)。
Cochrane Database Syst Rev. 2015 Mar 26(3):CD009841. doi: 10.1002/14651858.CD009841.pub2.
7
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.依伐卡托(Ataluren)及类似化合物(针对 I 类提前终止密码子突变的特异性治疗药物)治疗囊性纤维化。
Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD012040. doi: 10.1002/14651858.CD012040.pub3.
8
Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor.两种罕见的变异都会影响 CFTR 中的相同氨基酸,而对 ivacaftor 的反应却截然不同。
J Physiol. 2024 Jan;602(2):333-354. doi: 10.1113/JP285727. Epub 2024 Jan 7.
9
Macrolide antibiotics (including azithromycin) for cystic fibrosis.大环内酯类抗生素(包括阿奇霉素)治疗囊性纤维化。
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD002203. doi: 10.1002/14651858.CD002203.pub5.
10
Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.气道清除技术与囊性纤维化的非气道清除技术比较。
Cochrane Database Syst Rev. 2023 Apr 12;4(4):CD001401. doi: 10.1002/14651858.CD001401.pub4.

本文引用的文献

1
PERK signaling maintains hematopoietic stem cell pool integrity under endoplasmic reticulum stress by promoting proliferation.PERK信号通路通过促进增殖来维持内质网应激条件下造血干细胞库的完整性。
Blood. 2025 Aug 14;146(7):806-818. doi: 10.1182/blood.2024027846.
2
p.Phe508del-CFTR Trafficking: A Protein Quality Control Perspective Through UPR, UPS, and Autophagy.p.Phe508del-囊性纤维化跨膜传导调节因子转运:从未折叠蛋白反应、泛素-蛋白酶体系统及自噬角度看蛋白质质量控制
Int J Mol Sci. 2025 Apr 11;26(8):3623. doi: 10.3390/ijms26083623.
3
Insights into epithelial-mesenchymal transition from cystic fibrosis rat models.
从囊性纤维化大鼠模型中洞察上皮-间质转化
J Cyst Fibros. 2025 Jan;24(1):149-156. doi: 10.1016/j.jcf.2024.09.003. Epub 2024 Sep 12.
4
Endoplasmic reticulum stress-a key guardian in cancer.内质网应激——癌症中的关键守护者。
Cell Death Discov. 2024 Jul 30;10(1):343. doi: 10.1038/s41420-024-02110-3.
5
Exploring YAP1-centered networks linking dysfunctional CFTR to epithelial-mesenchymal transition.探讨以 YAP1 为中心的网络将功能失调的 CFTR 与上皮间质转化联系起来。
Life Sci Alliance. 2022 May 2;5(9). doi: 10.26508/lsa.202101326. Print 2022 Sep.
6
CFTR, Cell Junctions and the Cytoskeleton.CFTR、细胞连接和细胞骨架。
Int J Mol Sci. 2022 Feb 28;23(5):2688. doi: 10.3390/ijms23052688.
7
Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank.囊性纤维化 F508del 携带者与癌症风险:来自英国生物库的研究结果。
Int J Cancer. 2021 Apr 1;148(7):1658-1664. doi: 10.1002/ijc.33431. Epub 2020 Dec 18.
8
Mutant CFTR Drives TWIST1 mediated epithelial-mesenchymal transition.突变 CFTR 驱动 TWIST1 介导的上皮-间充质转化。
Cell Death Dis. 2020 Oct 26;11(10):920. doi: 10.1038/s41419-020-03119-z.
9
What Role Does CFTR Play in Development, Differentiation, Regeneration and Cancer?囊性纤维化跨膜传导调节因子(CFTR)在发育、分化、再生和癌症中扮演什么角色?
Int J Mol Sci. 2020 Apr 29;21(9):3133. doi: 10.3390/ijms21093133.
10
Guidelines and definitions for research on epithelial-mesenchymal transition.上皮-间质转化研究的指南和定义。
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352. doi: 10.1038/s41580-020-0237-9. Epub 2020 Apr 16.